Basic Information
| ID | DRAMP20926 |
|---|
| Sequence | LLPWKWPWWKWRR |
|---|
| Length | 13 |
|---|
| Name | IN1(designed based on indolicidin and ranalexin) |
|---|
| Source | Synthetic construct |
|---|
| Activity | Antimicrobial, Antibacterial, Anti-Gram+, Anti-Gram- |
|---|
| Pathogen | [Ref.26046345] Gram-negative bacteria: Escherichia coli ATCC 25922(MIC=31.25μg/ml), Pseudomonas aeruginosa ATCC 15442(MIC=31.25μg/ml), Acinetobacter baumanii ATCC 15308(MIC>250μg/ml), citrobacter spp(MIC>250μg/ml), Klebsiella pneumoniae(MIC>250μg/ml) ;## Gram-positive bacteria: Streptococcus pneumoniae(30 clinical isolates)(MIC=31.25–62.5μg/ml), Staphylococcus aureus ATCC 25923(MIC=31.25μg/ml), Methicillin resistant Staphylococcus aureus (MRSA)(MIC=31.25μg/ml), Enterococcus cloacae(MIC>250μg/ml), |
|---|
| Hemolytic Activity | [Ref.26046345] The hemolytic activities of IN1 is 3.6% at 250μg/ml against human RBCs. |
|---|
| Cytotoxicity | [Ref.26046345] The cell viability of NL-20 cell line is not affected (<10%) below 62.5 μg/ml. The cell viability of NL-20 is 37% and 17% at peptide concentrations of 125 and 250 μg/ml.## The cell viability of WRL-68 cell line is not affected (<10%) bel |
|---|
| N-terminal Modification | Free |
|---|
| C-terminal Modification | Amidation |
|---|
| Linear/Cyclic/Branched | Linear |
|---|
| Uniprot |
|
|---|
| PDB |
|
|---|
| 3D View | |
|---|
| PDB Download | Download PDB Predicted by Alphafold2 |
|---|
| PubMed ID | 26046345 |
|---|
